Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for C4 Therapeutics, Inc. Common Stock (CCCC).
- Disclosed ownership: 6.7%.
- Date of event: 30 Jun 2025.
MORGAN STANLEY - 30 Jun 2025 SCHEDULE 13G/A Report for C4 Therapeutics, Inc. Common Stock (CCCC)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- C4 Therapeutics, Inc. Common Stock
- Symbol
- CCCC
- Shares outstanding
- 70,901,239 shares
- Disclosed Ownership
- 4,750,383 shares
- Ownership
- 6.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 Aug 2025, 12:50:20 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 03 Feb 2025
- Next filing
- 11 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 6.7% ownership in C4 Therapeutics, Inc. Common Stock (CCCC) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 03 Feb 2025.
- Current filing was accepted on 07 Aug 2025, 12:50.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 6.7% | 4,750,383 | 0 | 4,749,421 | Christopher O'Hara | Authorized Signatory, Morgan Stanley |